Does Follicular Lymphoma Treatment Cause Secondary Cancers?

Yes, treatments for follicular lymphoma can sometimes cause secondary cancers later in life. While the overall risk is small, certain treatments like chemotherapy and radiation can damage healthy cells in your bone marrow, which may eventually lead to therapy-related blood cancers such as myelodysplastic syndrome (t-MDS) (where the bone marrow stops producing healthy blood cells) or acute myeloid leukemia (t-AML) (a fast-growing blood cancer) ^[1][2]. For most patients, balancing this risk involves looking at the data: standard treatments are highly effective at controlling follicular lymphoma and extending life, a primary benefit that many patients find heavily outweighs the small percentage risk of a secondary cancer ^[3][4].

Understanding the Risk and Timeline

When you receive systemic treatments or radiation for follicular lymphoma, the goal is to destroy the cancer cells. However, these treatments can also affect normal, healthy cells. Over time, the DNA in healthy bone marrow cells may become damaged, which is the underlying cause of secondary blood cancers ^[5][6].

These secondary cancers do not typically appear immediately. For common chemotherapy drugs, the risk of developing t-MDS or t-AML usually peaks around 5 to 10 years after you finish treatment ^[1][7]. The exact risk depends on a combination of factors, including your age, your natural genetics, and the specific types and doses of treatments you have received ^[5]. Research shows that older adults (over 65) and men may have a slightly higher baseline risk of developing secondary cancers ^[8].

How Specific Treatments Compare

Different treatments for follicular lymphoma carry different long-term risk profiles:

• Chemotherapy: Drugs known as alkylating agents (such as cyclophosphamide, used in the CHOP regimen) and purine analogs (like fludarabine) are strongly linked to an increased risk of t-MDS and t-AML ^[7][9].
• Bendamustine vs. R-CHOP: Bendamustine is a common chemotherapy drug used alongside rituximab (a regimen called BR). In a major 5-year follow-up study (the BRIGHT study), researchers observed a slightly higher number of secondary cancers (including skin and solid tumors) in patients treated with BR compared to those treated with R-CHOP or R-CVP ^[3]. However, long-term overall survival rates between these regimens remain similar, meaning the choice often depends on your specific health profile and how you and your doctor weigh the side effects ^[4][3].
• Radiation Therapy: Historically, wide-field radiation carried elevated risks for secondary solid tumors and blood cancers ^[8]. However, modern Involved-Site Radiation Therapy (ISRT) uses much lower doses and highly targeted fields. This modern technique is specifically designed to minimize the exposure of healthy tissue and significantly reduce the long-term risk of secondary cancers [A1HJWLB6].
• Stem Cell Transplants: Undergoing an autologous stem cell transplant (using your own stem cells) is a known risk factor for developing secondary blood cancers, primarily because it involves very high doses of chemotherapy ^[10][11].
• CAR-T Cell Therapy: While newer, targeted cellular therapies do not use traditional chemotherapy, they have their own specific safety profiles. CAR-T cell therapy (often used for relapsed lymphoma) carries a very rare but recognized risk of secondary T-cell malignancies, which requires lifelong monitoring ^[12][13].

Monitoring Your Long-Term Health

Because the risk of secondary cancer persists for years after treatment ends, long-term monitoring is a standard and essential part of your survivorship care ^[7]. Your care team will regularly check your blood counts during follow-up visits.

In the future, your doctor might mention specialized blood tests looking for clonal hematopoiesis ^[14]. This term refers to early, age-related genetic changes in blood cells. It is important to know that having clonal hematopoiesis is relatively common as people age and does not mean you have cancer; it simply means your care team may want to monitor your blood counts a bit more closely ^[15].

While you cannot completely control the genetic or treatment-related factors that drive these risks, you can stay vigilant. Always report new or lingering physical symptoms to your doctor between scheduled check-ups, especially extreme fatigue, easy bruising, unexplainable bleeding, or frequent infections, as these can be signs that your bone marrow is struggling to produce healthy blood cells.